Download full report with analyst certification and important disclosures
Aug 26 2026, 08:46 IST/BST
Malin Corporation
H1 2026 results
- Sectors : Pharma and healthcare
- Companies : Malin Corporation
DAVY VIEW
Malin has reported its H1 2026 results reflecting a NAV/share of €9.36, which is 2% growth during the period. However, the company previously reported on July 27th that it was writing down the value of its investment in Kymab to nil post period end. Its NAV/share at August 24th is €8.28, which is as expected.
